Article
Author: Kaiser, Astrid ; Schmachtel, Tessa ; Beck-Sickinger, Annette G ; Zaliani, Andrea ; Nevermann, Sheila ; Ivanov, Vladimir V ; Gribbon, Philipp ; Rieger, Michael A ; Wolf, Markus ; Merk, Daniel ; Haydo, Alicia S ; Sisignano, Marco ; Schermeng, Tina ; Ehrler, Johanna H M ; Offermanns, Stefan ; Moroz, Yurii S ; Heering, Jan ; Proschak, Ewgenij ; Höfner, Georg ; Alnouri, Mohamad Wessam ; Steinhilber, Dieter ; Marinescu, Beatrice ; Mathes, Marius ; Schubert-Zsilavecz, Manfred ; Hernandez-Olmos, Victor
G protein-coupled receptor G2A was postulated to be a promising target for the development of new therapeutics in neuropathic pain, acute myeloid leukemia, and inflammation. However, there is still a lack of potent, selective, and drug-like G2A agonists to be used as a chemical tool or as the starting matter for the development of drugs. In this work, we present the discovery and structure-activity relationship elucidation of a new potent and selective G2A agonist scaffold. Systematic optimization resulted in (3-(pyridin-3-ylmethoxy)benzoyl)-d-phenylalanine (T-10418) exhibiting higher potency than the reference and natural ligand 9-HODE and high selectivity among G protein-coupled receptors. With its favorable activity, a clean selectivity profile, excellent solubility, and high metabolic stability, T-10418 qualifies as a pharmacological tool to investigate the effects of G2A activation.